What outcome is expected from a Tensilon Test in a patient diagnosed with Myasthenia Gravis?

In a patient diagnosed with Myasthenia Gravis, a Tensilon Test, which involves the administration of edrophonium chloride, is expected to result in a dramatic increase in muscle strength. This is due to the mechanism of the drug, which is an acetylcholinesterase inhibitor that temporarily increases the levels of acetylcholine at the neuromuscular junction.

Myasthenia Gravis is characterized by an autoimmune response leading to the destruction of acetylcholine receptors, resulting in muscle weakness. When edrophonium chloride is given, it inhibits the breakdown of acetylcholine, allowing more of it to be available for binding to the remaining receptors. As a result, patients often experience a marked improvement in muscle strength shortly after administration.

This dramatic increase can be observed with muscle groups affected by the disease, which can provide diagnostic confirmation of Myasthenia Gravis. The rapid and positive response to the Tensilon Test serves as an important clinical tool in both diagnosing and managing the condition.